CPNPC avancé : amélioration de la survie à cinq ans avec le pembrolizumab

L'inhibiteur PD-1 pembrolizumab améliore significativement le taux de survie à 5 ans des patients atteints de cancer du poumon non à petites cellules (CPNPC). Une efficacité particulièrement remarquable chez les patients dont l'expression PD-L1 est élevée (article en anglais).

Longer survival due to higher PD-L1 expression levels

The PD-1 inhibitor pembrolizumab (Keytruda) significantly improves the 5-year survival rates of patients with non-small cell lung cancer (NSCLC). The effect was particularly good in patients with high PD-L1 expression.

These findings were obtained by a long-term evaluation of the Phase I study KEYNOTE 001, which was started in 2011 and presented as a poster by Edward B. Garon; David Geffen School of Medicine, Los Angeles, California, USA at the annual meeting of the American Society for Clinical Oncology (ASCO) on June 2, 2019. After 5 years, 23.2% of the patients not pretreated with chemotherapy and 15.5% of the pretreated patients were still alive.

The PD1 inhibitor pembrolizumab was initially approved in 2014 for the treatment of melanoma, but can now be used in a variety of tumors, including NSCLC in various therapy lines and tumor stages. The KEYNOTE-001 Phase 1 trial was the first clinical trial to use pembrolizumab in patients with multiple tumors. In the study, 555 patients with advanced NSCLC received pembrolizumab 2mg mg/kg body weight every 3 weeks or 10mg/kg body weight every 2 to 3 weeks. Today, pembrolizumab is administered as a single dose of 200mg every 3 weeks, regardless of body weight. Of the 550 participants, 449 were pretreated, 101 received the PD-1 inhibitor as first-line therapy.

Follow-up over more than 60 months

Patients were monitored for a median of 60.6 months. After this time, 100 participants (18%) were still alive, 23.3% who had not received pre-treatment and 15.5% who had received pre-treatment. Higher PD-L1 levels increased the chance of longer survival. After 5 years, 29.6% of patients still lived without pretreatment with PD-L1 expression of at least 50% compared to 15.7% with PD-L1 expression below 50%. The corresponding figures for the pretreated patients: 12.6% with high PD-L1 expression, 3.5% with lower PD-L1 expression.

The response rate of pretreated patients was 42% and the median response time was 16.8 months. The response rate of untreated patients was 23% with a duration of 38.9 months.

A total of 60 patients had received pembrolizumab for at least 2 years. Of these, 46 were still alive at the time of the current evaluation.

Immunotoxic effects were observed in 17% of patients, with hypothyroidism most common with an incidence of 8 to 9%. Pneumonitis was registered in about 4% of the cases, half from grade 3 to 5.

"The fact that we have patients in this study who are still alive even after 7 years is quite remarkable," Garon said at an ASCO press conference. "We also note that most patients who are doing well after 2 years of pembrolizumab are also achieving the 5-year survival mark - and even longer."

ASCO expert David L. Graham, Levine Cancer Institute, Charlotte, North Carolina, USA, commented at the press conference: "These data correspond to what we see with immunotherapy in other cancers: There is a patient population that survives 5 and more years. It is remarkable that we are no longer able to calculate survival times in months for more and more patients, but in years". Previously, only about 5% or less of patients with metastatic NSCLC survived 5 years. However, Graham added, "We still have a long way to go to improve outcomes for all patients with advanced lung cancer."

Garon EB, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. 2019 ASCO Annual Meeting, Chicago, May 31 to June 4, 2019, Abstract LBA9015.http://abstracts.asco.org/239/AbstView_239_255115.html

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.